- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Glaucoma research benefit celebrates scientists
Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation (GRF) Catalyst Award at the organization's annual benefit and celebration.
San Francisco-Jeffrey B. Kindler, chief executive officer (CEO) and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation (GRF) Catalyst Award at the organization's annual benefit and celebration.
The award recognizes outstanding accomplishments in research and education in support of those affected by glaucoma.
Also at the event, the principal investigators in the Catalyst for a Cure consortium funded by the foundation updated attendees on their latest results. The scientists are David Calkins, PhD, Vanderbilt University; Philip Horner, PhD, University of Washington; Nicholas Marsh-Armstrong, PhD, Johns Hopkins University; and Monica Vetter, PhD, University of Utah.
